Dexmedetomidine
| Dexmedetomidine | |
|---|---|
| Salts [] | |
|---|---|
| Dexmedetomidine hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 200.28 g/mol [1] |
| Solubility | Freely soluble in water [1] |
| Predicted LogP | 3.1 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C13H16N2 |
| IUPAC name | 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole |
| SMILES | CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C |
| InChI | InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1 |
| InChIKey | CUHVIMMYOGQXCV-NSHDSACASA-N |
| CAS number | 113775-47-6 |
| UNII | 67VB76HONO |
| PubChem CID | 5311068 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 1.8–3.7 hours[3] |
| Metabolism | Near-complete hepatic metabolism to inactive metabolites |
| Excretion | Urine (95%), feces (4%) |
| Routes of administration | Intravenous, sublingual, buccal |
Dexmedetomidine (also known as Dexmedetomidina, Dexmedetomidinum, Mpv 1440, Mpv-1440, Medetomidine, (s)-, (+)-4-((S)-α,2,3-Trimethylbenzyl)imidazole, 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, 4-((1S)-1-(2,3-dimethylphenyl)ethyl)-1H-imidazole, 4-((1S)-1-(2,3-dimethylphenyl)ethyl)-3H-imidazole or 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-3H-imidazole) is a substance of the phenethylamine class.
Chemistry
Salts []
Stereochemistry []
Dexmedetomidine is a single defined stereoisomer (optical activity ( + )).
Druglikeness
Lipinski's rule of five
Dexmedetomidine matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- psycholeptics (N05)
- hypnotics and sedatives (N05C)
- other hypnotics and sedatives (N05CM)
- dexmedetomidine (N05CM18)
MeSH Classification
- hypnotics and sedatives (M0010885)
- analgesics, non-narcotic (M0028038)
- adrenergic alpha-2 receptor agonists (M0543921)
Mechanism of action []
Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CYP2D6 | metabolism / inhibition / induction | 18 |
|---|---|---|
| CYP2C19 | metabolism / inhibition / induction | 17 |
| CYP2A6 | inhibition / metabolism | 4 |
| ADRA2A | shared target | 3 (2 contraindicated) |
| CYP2E1 | metabolism | 3 |
| ADRA2B | shared target | 2 (2 contraindicated) |
| ADRA2C | shared target | 2 (2 contraindicated) |
Medical side effects []
136 side effects listed on drug labels in SIDER 4.1 (dexmedetomidine).
- Systolic hypertension
- Respiratory depression
- Pulmonary function test decreased
- Hypotension
- Diastolic hypertension
- Hypertension
- Hypertension worsened
- Hypokalaemia
- Hypomagnesaemia
- Constipation
- Generalised oedema
- Fluid retention
- Hypoglycaemia
- Infarction
- Withdrawal syndrome
- Tachycardia
- Myocardial ischaemia
- Bradycardia
- Atrial fibrillation
- Respiratory failure
- Hypoventilation
- Atelectasis
- Pneumothorax
- Nausea
- Vomiting
- Dry mouth
- Body temperature increased
- Anaemia
- Hyperglycaemia
- Pleural effusion
- Chills
- Rigors
- Agitation
- Respiratory rate decreased
- Hypoxia
- Post procedural haemorrhage
- Hypovolaemia
- Renal failure acute
- Acute respiratory distress syndrome
- Acidosis
- Hypocalcaemia
- Oliguria
- Pulmonary oedema
- Sinus tachycardia
- Wheezing
- Abdominal distension
- Cardiac output decreased
- Atrioventricular block first degree
- Metabolic acidosis
- Hypoalbuminaemia
- Drug ineffective
- Oedema peripheral
- Ventricular tachycardia
- Abdominal pain
- Gastrointestinal pain
- Respiratory acidosis
- Apnoea
- Arrhythmia
- Atrioventricular block
- Block heart
- Mental disorder
- Bronchospasm
- Cardiovascular disorder
- Confusional state
- Feeling abnormal
- Delirium
- Diarrhoea
- Dizziness
- Dyspnoea
- Hallucination
- Headache
- Cardiac arrest
- Cardiac disorder
- Haemorrhage
- Haemoglobin
- Hyperbilirubinaemia
- Hypercapnia
- Carbon dioxide increased
- Hyperkalaemia
- Illusion
- Nephropathy
- Myocardial infarction
- Acute coronary syndrome
- Neuralgia
- Neuritis
- Neuropathy peripheral
- Pain
- Convulsion
- Speech disorder
- Supraventricular tachycardia
- Thirst
- Angiopathy
- Visual impairment
- Abnormal vision
- Ventricular arrhythmia
- Photopsia
- Hepatic function abnormal
- Blood urea increased
- Urea increased
- Blood alkaline phosphatase increased
- Malnutrition
- Pulmonary congestion
- Respiratory tract congestion
- Extrasystoles
- Hyperpyrexia
- Light anaesthesia
- Electrocardiogram T wave inversion
- Blood pressure fluctuation
- Hyperhidrosis
- Anxiety
- Infection
- Decubitus ulcer
- Dermatitis
- Rash
- Gastrointestinal disorder
- Hypernatraemia
- Body temperature decreased
- Hypothermia
- Leukocytosis
- Mediastinal disorder
- Pneumonia
- Pregnancy
- Septic shock
- Thrombocytopenia
- Urinary tract infection
- Hypophosphataemia
- Gamma-glutamyltransferase increased
- Aspartate aminotransferase increased
- Alanine aminotransferase increased
- Haemoglobin decreased
- Sepsis
- Electrolyte imbalance
- Sinus arrest
- Fluid overload
- Laryngeal pain
- Somnolence
Indications
- Agitation
- Bradycardia
Subjective effects []
| bonzi / Dexmedetomidine [] | |
|---|---|
Legal status []
See also []
External links []
- Dexmedetomidine (Wikipedia)
- Dexmedetomidine (PubChem)
- Dexmedetomidine (Wikidata)
- Dexmedetomidine (DrugBank)
- Dexmedetomidine (ChEMBL)
- Dexmedetomidine (ChEBI)
- Dexmedetomidine (Common Chemistry)
- Dexmedetomidine (HMDB)
- Dexmedetomidine (KEGG)
- Dexmedetomidine (EPA DSSTox)
- Dexmedetomidine (Effect Index)
- Dexmedetomidine (UNII)
- Dexmedetomidine (SIDER)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5311068, Dexmedetomidine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5311068
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Dexmedetomidine. UNII: 67VB76HONO. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/67VB76HONO
Precedex-Label. www.accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021038s061lbl.pdf
DEXMEDETOMIDINE FRESENIUS (Fresenius Kabi Australia Pty Ltd). Department of Health and Aged Care. https://www.tga.gov.au/resources/prescription-medicines-registrations/dexmedetomidine-fresenius-fresenius-kabi-australia-pty-ltd
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Precedex- dexmedetomidine hydrochloride injection, solution. DailyMed. 2 March 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4419162d-81d4-49bd-96de-1729440bdb74
Igalmi- dexmedetomidine film. DailyMed. 14 December 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99476e8c-2527-4cb0-9d67-9f9cd91343c6
Sileo EPAR. European Medicines Agency. 7 July 2015. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/sileo
Dexdomitor EPAR. European Medicines Agency (EMA). 14 December 2009. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/dexdomitor
Dexdomitor PI. Union Register of medicinal products. 5 September 2002. https://ec.europa.eu/health/documents/community-register/html/v033.htm
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 06:05:54 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 06:05:50 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 06:05:50 |
| gsrs | ok | 2026-11-20 06:05:51 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014771) | 2026-11-20 06:05:50 |
| kegg | ok | 2026-11-20 06:05:52 |
| pubchem | ok | 2026-11-20 06:05:50 |
| missing (no r/tripreports posts mention it) | 2026-11-20 06:05:50 | |
| sider | ok | 2026-11-20 06:05:51 |
| structure | ok | 2026-11-20 06:05:50 |
| wikipedia | ok | 2026-11-20 06:05:51 |